Work Package 1 – Long-term sustainability & access procedures

Lead: EU-OS

The activities under WP1 are designed to ensure the long-term sustainability of EU-OPENSCREEN so that it can continue to provide top-tier services to the scientific community. To this end, WP1 will support the integration of the novel services and methods developed within IMPULSE into the EU-OPENSCREEN framework, thereby making them more readily available to scientific collaborators. WP1 will also engage with candidate member countries and potential funders within and beyond Europe to secure the research infrastructure’s long-term financial stability.

Work Package 2 – Creating a repository of community compounds

Lead: USC

Under EU-OPENSCREEN's compound-sharing initiative, chemists are invited to donate compounds to the European Academic Compound Library (EACL), where they will be assessed for biological activity in a set of bioprofiling assays. This compound submission process aims to catalyse cooperation between chemists and biologists, facilitated by the expertise of the EU-OPENSCREEN screening centres within an IP-sharing model that rewards all parties.

WP2 aims to bolster this compound-sharing initiative by proactively engaging with chemists via a network of ambassadors from EU-OPENSCREEN member countries to explain the benefits of submitting compounds. WP2 will also streamline the processes for transferring submitted compounds, running bioprofiling assays and sharing the resulting data.

Work Package 3 – Validating pharmacology using advanced disease models & genetic screens

Lead: KI & UC

Successful preclinical drug discovery depends heavily on the ability of experimental cell models to mirror human pathophysiology. As such, WP3 aims to establish capabilities and workflows for bioactive hit validation in complex and high-fidelity cellular disease models. Expertise in advanced disease models and genetic screening tools will be mapped across the consortium, and demonstrator/technology development projects will be launched to leverage cross-consortium synergies for future users of EU-OPENSCREEN's services.

Work Package 4 – New chemical modalities

Lead: CSIC

To complement the current EU-OPENSCREEN medicinal chemistry portfolio, WP4 is developing new chemical modalities beyond the traditional small molecules to attack more challenging biological targets. These new modalities include new chemical probes (fluorescent, activity-based and traceless proximity probes), targeted degraders (e.g., heterobifunctional degraders like PROTACs or RIBOTACs), enzymatic modulators and multi-target molecules associated with polypharmacology.

Through close collaboration between medicinal chemistry and screening partner sites, these services will be rigorously developed and validated in demonstrator projects. When integrated into the EU-OPENSCREEN portfolio, these services will facilitate the development of chemical probes, smart drug candidates and emergent therapeutic approaches.

Inhalt oben

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.